Distinct neuroinflammatory profiles in progressive supranuclear palsy associated with <i>HLA</i> haplotypes.

Research overview

The text below is the source article’s original abstract under a verified reuse license. cc by

Progressive supranuclear palsy is a neurodegenerative four-repeat tauopathy characterized by atypical parkinsonism and cognitive behavioural changes and a relatively uniform neuropathology. Building on prior identification of rare HLA (human leukocyte antigen) haplotypes in progressive supranuclear palsy, this study investigates whether these haplotypes correlate with distinct clinical and immunopathological phenotypes. In addition to retrospective collection of clinical data, we evaluated T and B cells, microglia and phosphorylated-tau (p-Tau) cytopathologies in 32 progressive supranuclear palsy cases. Machine learning was used to analyse whether pathological variables and their ratios, or the sequence of clinical symptoms are different HLA-defined groups, including one linked to narcolepsy (DRB1*15:01-DQB1*06:02). Neuropathology revealed regional differences in the severity of microglia load, density of cytotoxic T cells and p-Tau cytopathologies between groups. Machine learning revealed that specific ratios of neuroinflammatory markers reliably distinguished HLA haplotypes. Additionally, symptom progression sequences varied by HLA haplotype, suggesting a potential effect of neuroinflammatory profiles on disease trajectory. These findings support the notion that progressive supranuclear palsy pathology might be associated with various aetiological-pathogenic events rarely including targetable autoimmune mechanisms as well. The HLA haplotype-dependent diversity of neuroinflammatory markers should be evaluated in clinical and biomarker studies in, and beyond, progressive supranuclear palsy to understand its relevance for patient stratification in disease modifying therapy trials.

Related topics